[Federal Register Volume 88, Number 59 (Tuesday, March 28, 2023)]
[Notices]
[Page 18324]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-06358]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Diabetes Mellitus Interagency Coordinating Committee 
Meeting

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee 
(DMICC) will hold a meeting on April 24, 2023. The topic for this 
meeting will be ``Type 1 Diabetes (T1D): Evolving Concepts in the 
Pathophysiology, Screening and Prevention''. The meeting is open to the 
public.

DATES: The meeting will be held on April 24, 2023 from 12:00 p.m. to 
4:00 p.m. EST.

ADDRESSES: The meeting will be held via the Zoom online video 
conferencing platform. For details, and to register, please contact 
[email protected].

FOR FURTHER INFORMATION CONTACT: For further information concerning 
this meeting, including a draft agenda, which will be posted when 
available, see the DMICC website, www.diabetescommittee.gov, or contact 
Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus 
Interagency Coordinating Committee, National Institute of Diabetes and 
Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, 
Room 6037, Bethesda, MD 20892, telephone: 301-435-1011; email: 
[email protected].

SUPPLEMENTARY INFORMATION: In accordance with 42 U.S.C. 285c-3, the 
DMICC, chaired by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) comprising members of the Department of Health 
and Human Services and other federal agencies that support diabetes-
related activities, facilitates cooperation, communication, and 
collaboration on diabetes among government entities. DMICC meetings, 
held several times a year, provide an opportunity for Committee members 
to learn about and discuss current and future diabetes programs in 
DMICC member organizations and to identify opportunities for 
collaboration. The April 24, 2023 DMICC meeting will focus on ``Type 1 
Diabetes (T1D): Evolving Concepts in the Pathophysiology, Screening and 
Prevention.''
    Any member of the public interested in presenting oral comments to 
the Committee should notify the contact person listed on this notice at 
least 5 days in advance of the meeting. Interested individuals and 
representatives or organizations should submit a letter of intent, a 
brief description of the organization represented, and a written copy 
of their oral presentation in advance of the meeting. Only one 
representative of an organization will be allowed to present; oral 
comments and presentations will be limited to a maximum of 5 minutes. 
Printed and electronic copies are requested for the record. In 
addition, any interested person may file written comments with the 
Committee by forwarding their statement to the contact person listed on 
this notice. The statement should include the name, address, telephone 
number and when applicable, the business or professional affiliation of 
the interested person. Because of time constraints for the meeting, 
oral comments will be allowed on a first-come, first-serve basis.
    Members of the public who would like to receive email notification 
about future DMICC meetings should register for the listserv available 
on the DMICC website, www.diabetescommittee.gov.

William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, 
National Institute of Diabetes and Digestive and Kidney Diseases, and 
Metabolic Diseases, National Institutes of Health.
[FR Doc. 2023-06358 Filed 3-27-23; 8:45 am]
BILLING CODE 4140-01-P